Cassava Sciences, Inc. (SAVA) Research

Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.

Market snapshot

Symbol
SAVA
Price
$1.32
Day change
+2.33%
Market cap
$58.9M
P/E ratio
-0.76x
52-week range
1.15-4.98
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Alector, Inc. (ALEC)
  • Cardiff Oncology, Inc. (CRDF)
  • Cybin Inc. (CYBN)
  • Elicio Therapeutics, Inc. (ELTX)
  • Fate Therapeutics, Inc. (FATE)
  • Milestone Pharmaceuticals Inc. (MIST)
  • Molecular Partners AG (MOLN)
  • Nkarta, Inc. (NKTX)

Recent insider activity

  • Anderson Robert Eugene Jr — P-Purchase (8600 shares) on 2025-11-24
  • Barry Richard — P-Purchase (150000 shares) on 2025-11-20
  • Barry Richard — P-Purchase (73385 shares) on 2025-11-19
  • Bir Dawn Carter — A-Award (53000 shares) on 2025-10-21
  • Bir Dawn Carter — trade (0 shares) on 2025-10-21

Open Cassava Sciences, Inc. (SAVA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.